edaravone has been researched along with Acute Confusional Senile Dementia in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone treatment significantly elevated cell viability, reduced apoptotic rate, attenuated oxidative stress and improved mitochondrial membrane potential in N2a/Swe." | 5.38 | Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells. ( Gong, K; Gong, Y; Ma, T; Tang, P; Yan, Y; Zhang, L; Zhang, X; Zhao, N, 2012) |
| " The present study demonstrates that the long-term administration of EDA may provide a promising therapeutic approach for WMLs in AD plus CCH disease with cognitive deficits." | 1.62 | Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion. ( Abe, K; Feng, T; Hishikawa, N; Matsumoto, N; Sasaki, R; Tadokoro, K; Yamashita, T, 2021) |
| "Our results indicate that oral delivery of NEF holds a promise as a safe and effective therapeutic agent for AD." | 1.48 | Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model. ( Cao, X; Chen, C; Garg, S; Kathawala, K; Li, J; Parikh, A; Shan, Z; Wang, YJ; Zhou, XF, 2018) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "Edaravone is a potent free radical scavenger that exerts antioxidant effects." | 1.42 | Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease. ( Li, F; Li, J; Liu, X; Wang, Q; Yang, R, 2015) |
| "Treatment with edaravone significantly improved STZ-induced cognitive damage as evaluated in Morris water maze and step-down tests and markedly restored changes in malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) adducts, hydroxyl radical (OH), hydrogen peroxide (H2O2), total superoxide dismutase (T-SOD), reduced glutathione (GSH), glutathione peroxidase (GPx) and protein carbonyl (PC) levels." | 1.39 | Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. ( Chi, L; Yu, G; Zhang, L; Zhang, W; Zhang, Y; Zhou, S; Zhu, J, 2013) |
| "Edaravone is a novel free radical scavenger currently used to reduce cerebral damages after acute cerebral infarction." | 1.39 | Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells. ( Liu, C; Shen, YE; Wang, Y; Yu, GC; Zhang, LM; Zhang, ZY, 2013) |
| "Edaravone treatment significantly elevated cell viability, reduced apoptotic rate, attenuated oxidative stress and improved mitochondrial membrane potential in N2a/Swe." | 1.38 | Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells. ( Gong, K; Gong, Y; Ma, T; Tang, P; Yan, Y; Zhang, L; Zhang, X; Zhao, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Qiang, X | 1 |
| Li, Y | 1 |
| Yang, X | 1 |
| Luo, L | 1 |
| Xu, R | 1 |
| Zheng, Y | 1 |
| Cao, Z | 1 |
| Tan, Z | 1 |
| Deng, Y | 1 |
| Li, HN | 1 |
| Liu, Y | 1 |
| Zhang, ZP | 1 |
| Wang, ZP | 1 |
| Hao, JZ | 1 |
| Li, FR | 1 |
| Fan, ZF | 1 |
| Zou, LB | 1 |
| Cheng, MS | 1 |
| Yu, H | 1 |
| Yamashita, T | 4 |
| Hu, X | 2 |
| Bian, Z | 1 |
| Feng, T | 3 |
| Tadokoro, K | 4 |
| Morihara, R | 2 |
| Abe, K | 4 |
| Guo, S | 1 |
| Lei, Q | 1 |
| Guo, H | 1 |
| Yang, Q | 1 |
| Xue, Y | 1 |
| Chen, R | 1 |
| Anoush, M | 1 |
| Bijani, S | 1 |
| Moslemifar, F | 1 |
| Jahanpour, F | 1 |
| Kalantari-Hesari, A | 1 |
| Hosseini, MJ | 1 |
| Oosthoek, M | 1 |
| Lili, A | 1 |
| Almeida, A | 1 |
| van Loosbroek, O | 1 |
| van der Geest, R | 1 |
| de Greef-van der Sandt, I | 1 |
| van Bokhoven, P | 1 |
| Sikkes, SAM | 1 |
| Teunissen, CE | 1 |
| Vijverberg, EGB | 1 |
| Shang, J | 2 |
| Shi, X | 2 |
| Nakano, Y | 2 |
| Tsunoda, K | 2 |
| Nomura, E | 2 |
| Sasaki, R | 3 |
| Matsumoto, N | 2 |
| Hishikawa, N | 3 |
| Ohta, Y | 2 |
| Tian, F | 1 |
| Li, X | 1 |
| Liu, X | 2 |
| Sato, K | 1 |
| Takemoto, M | 1 |
| Zondagh, LS | 1 |
| Malan, SF | 1 |
| Joubert, J | 1 |
| Kapoor, S | 1 |
| Parikh, A | 2 |
| Kathawala, K | 1 |
| Li, J | 3 |
| Chen, C | 1 |
| Shan, Z | 1 |
| Cao, X | 1 |
| Wang, YJ | 2 |
| Garg, S | 1 |
| Zhou, XF | 2 |
| Zhang, L | 3 |
| Guo, Y | 1 |
| Wang, H | 1 |
| Zhao, L | 1 |
| Ma, Z | 1 |
| Li, T | 1 |
| Liu, J | 3 |
| Sun, M | 1 |
| Jian, Y | 1 |
| Yao, L | 1 |
| Du, Y | 1 |
| Zhang, G | 1 |
| Zhou, S | 1 |
| Yu, G | 1 |
| Chi, L | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Zhang, Y | 1 |
| He, F | 1 |
| Cao, YP | 1 |
| Che, FY | 1 |
| Yang, LH | 1 |
| Xiao, SH | 1 |
| Jiao, SS | 1 |
| Yao, XQ | 1 |
| Liu, YH | 1 |
| Wang, QH | 1 |
| Zeng, F | 1 |
| Lu, JJ | 1 |
| Zhu, C | 1 |
| Shen, LL | 1 |
| Liu, CH | 1 |
| Wang, YR | 1 |
| Zeng, GH | 1 |
| Chen, J | 1 |
| Liang, CR | 1 |
| Xiang, Y | 1 |
| Bu, XL | 1 |
| Deng, J | 1 |
| Xu, J | 1 |
| Zeng, YQ | 1 |
| Xu, X | 1 |
| Xu, HW | 1 |
| Zhong, JH | 1 |
| Zhou, HD | 1 |
| Yang, R | 1 |
| Wang, Q | 1 |
| Li, F | 1 |
| Yan, Y | 1 |
| Gong, K | 1 |
| Ma, T | 1 |
| Zhao, N | 1 |
| Zhang, X | 1 |
| Tang, P | 1 |
| Gong, Y | 1 |
| Shen, YE | 1 |
| Wang, Y | 1 |
| Yu, GC | 1 |
| Liu, C | 1 |
| Zhang, ZY | 1 |
| Zhang, LM | 1 |
1 trial available for edaravone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease Patients.
Topics: Alzheimer Disease; Biomarkers; Edaravone; Humans; Neurodegenerative Diseases; Randomized Controlled | 2023 |
18 other studies available for edaravone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Synthesis, biological evaluation and structure-activity relationship studies of hederacolchiside E and its derivatives as potential anti-Alzheimer agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Dose-Response Rel | 2018 |
Protective and anti-oxidative effects of curcumin and resveratrol on Aβ-oligomer-induced damage in the SH-SY5Y cell line.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Curcumin; Edaravone; Free Radical Scaven | 2022 |
Edaravone Attenuates Aβ 1-42-Induced Inflammatory Damage and Ferroptosis in HT22 Cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Edaravone; Ferroptosis; Humans; Neuroprotective Agents; NF | 2023 |
Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Donepezil; Edaravone; Inflammation | 2023 |
Clinical and Pathological Benefits of Edaravone for Alzheimer's Disease with Chronic Cerebral Hypoperfusion in a Novel Mouse Model.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Male; Mice; Mice, Tra | 2019 |
Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer's disease model mouse.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barri | 2019 |
Design, synthesis and biological evaluation of edaravone derivatives bearing the
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2020 |
Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Male; Mice; Neuroprot | 2021 |
Edaravone and Its Protective Effects against Disease Progression in Neurological Conditions Besides Strokes.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Edaravone; Humans; | 2017 |
Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model.
Topics: Administration, Oral; Alzheimer Disease; Animals; Cell Line, Tumor; Disease Models, Animal; Dose-Res | 2018 |
Edaravone reduces Aβ-induced oxidative damage in SH-SY5Y cells by activating the Nrf2/ARE signaling pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidant Response Elements; Apoptosis; Cell Li | 2019 |
Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats.
Topics: Alzheimer Disease; Animals; Antipyrine; Cognition Disorders; Edaravone; Free Radical Scavengers; Inf | 2013 |
Inhibitory effects of edaravone in β-amyloid-induced neurotoxicity in rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipyrine; CA1 Region, Hippocampal; Disease Mode | 2014 |
Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.
Topics: Administration, Oral; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Antipyrine; Behavi | 2015 |
Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease.
Topics: Acetylcholinesterase; Aldehydes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipyrine; Chol | 2015 |
Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells.
Topics: Alzheimer Disease; Animals; Antipyrine; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Surviva | 2012 |
Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Antipyrine; Cell Line, Tumor; Cell Survival; Dose | 2013 |